Cargando…
Identifying pathological biomarkers: histochemistry still ranks high in the omics era
In recent years, omic analyses have been proposed as possible approaches to diagnosis, in particular for tumours, as they should be able to provide quantitative tools to detect and measure abnormalities in gene and protein expression, through the evaluation of transcription and translation products...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3284244/ https://www.ncbi.nlm.nih.gov/pubmed/22297448 http://dx.doi.org/10.4081/ejh.2011.e42 |
_version_ | 1782224339732529152 |
---|---|
author | Pellicciari, C. Malatesta, M. |
author_facet | Pellicciari, C. Malatesta, M. |
author_sort | Pellicciari, C. |
collection | PubMed |
description | In recent years, omic analyses have been proposed as possible approaches to diagnosis, in particular for tumours, as they should be able to provide quantitative tools to detect and measure abnormalities in gene and protein expression, through the evaluation of transcription and translation products in the abnormal vs normal tissues. Unfortunately, this approach proved to be much less powerful than expected, due to both intrinsic technical limits and the nature itself of the pathological tissues to be investigated, the heterogeneity deriving from polyclonality and tissue phenotype variability between patients being a major limiting factor in the search for unique omic biomarkers. Especially in the last few years, the application of refined techniques for investigating gene expression in situ has greatly increased the diagnostic/prognostic potential of histochemistry, while the progress in light microscopy technology and in the methods for imaging molecules in vivo have provided valuable tools for elucidating the molecular events and the basic mechanisms leading to a pathological condition. Histochemical techniques thus remain irreplaceable in pathologist's armamentarium, and it may be expected that even in the future histochemistry will keep a leading position among the methodological approaches for clinical pathology. |
format | Online Article Text |
id | pubmed-3284244 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | PAGEPress Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-32842442012-02-23 Identifying pathological biomarkers: histochemistry still ranks high in the omics era Pellicciari, C. Malatesta, M. Eur J Histochem Views and Comments In recent years, omic analyses have been proposed as possible approaches to diagnosis, in particular for tumours, as they should be able to provide quantitative tools to detect and measure abnormalities in gene and protein expression, through the evaluation of transcription and translation products in the abnormal vs normal tissues. Unfortunately, this approach proved to be much less powerful than expected, due to both intrinsic technical limits and the nature itself of the pathological tissues to be investigated, the heterogeneity deriving from polyclonality and tissue phenotype variability between patients being a major limiting factor in the search for unique omic biomarkers. Especially in the last few years, the application of refined techniques for investigating gene expression in situ has greatly increased the diagnostic/prognostic potential of histochemistry, while the progress in light microscopy technology and in the methods for imaging molecules in vivo have provided valuable tools for elucidating the molecular events and the basic mechanisms leading to a pathological condition. Histochemical techniques thus remain irreplaceable in pathologist's armamentarium, and it may be expected that even in the future histochemistry will keep a leading position among the methodological approaches for clinical pathology. PAGEPress Publications 2011-12-07 /pmc/articles/PMC3284244/ /pubmed/22297448 http://dx.doi.org/10.4081/ejh.2011.e42 Text en ©Copyright C. Pellicciari and M. Malatesta, 2011 This work is licensed under a Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0). Licensee PAGEPress, Italy |
spellingShingle | Views and Comments Pellicciari, C. Malatesta, M. Identifying pathological biomarkers: histochemistry still ranks high in the omics era |
title | Identifying pathological biomarkers: histochemistry still ranks high in the omics era |
title_full | Identifying pathological biomarkers: histochemistry still ranks high in the omics era |
title_fullStr | Identifying pathological biomarkers: histochemistry still ranks high in the omics era |
title_full_unstemmed | Identifying pathological biomarkers: histochemistry still ranks high in the omics era |
title_short | Identifying pathological biomarkers: histochemistry still ranks high in the omics era |
title_sort | identifying pathological biomarkers: histochemistry still ranks high in the omics era |
topic | Views and Comments |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3284244/ https://www.ncbi.nlm.nih.gov/pubmed/22297448 http://dx.doi.org/10.4081/ejh.2011.e42 |
work_keys_str_mv | AT pellicciaric identifyingpathologicalbiomarkershistochemistrystillrankshighintheomicsera AT malatestam identifyingpathologicalbiomarkershistochemistrystillrankshighintheomicsera |